Adverse events · children with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every 4 weeks showed no clear difference in adverse events at ≥ 12 months compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in adverse events at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Adverse events (not measured) · children with cerebral palsy classified within GMFCS Levels I to IV and between 4 and 18 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (not measured) · children with cerebral palsy classified within GMFCS Levels I to III and between 3 and 12 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ not reported · patients with chronic neck pain (pain for more than 90 days)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of serious adverse events · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)
2 findings from 1 review
Rate of serious adverse events · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review
Total number of adverse events · Children aged 6 to 18 years with ASD
2 findings from 1 review
Adverse events (any) · children (4 to 18 years) with functional abdominal pain disorders
It is very uncertain whether synbiotic changes adverse events (any) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events (any) · children (4 to 18 years) with functional abdominal pain disorders
It is very uncertain whether probiotic changes adverse events (any) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes withdrawal due to adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Incidence of skin adverse events · children (age < 18 years) susceptible to acute respiratory tract infections (ARTIs)
1 finding from 1 review
Adverse events Participant events · adults aged 18 years and older receiving palliative care
1 finding from 1 review